Global Phage Therapy Market Revenue, Growth, and Definition Insights Based on Type, Application, Region, and Player from 2024 to 2029

1.Global Phage Therapy Market Definition

The global Phage Therapy market is poised for significant growth, with a revenue of $208.08 million in 2024 with a CAGR of 10.91% from 2024 to 2029.

Phage Therapy, formally known as bacteriophage therapy, involves the use of viruses that specifically target and destroy bacteria. These viruses, known as bacteriophages, are the most common biological entities in nature and have been shown to effectively combat multi-drug resistant bacteria. When all antibiotics fail, phages can still kill the bacteria, potentially saving lives from infections. Phage therapy has many potential applications in human medicine, veterinary science, and agriculture.

Global Phage Therapy Market Size (M USD) in 2024

2. Driving and Limiting Factors of Phage Therapy Market

Increasing Prevalence of Antibiotic-Resistant Infections: The rise in antibiotic-resistant infections is a major driver for the Phage Therapy market. As traditional antibiotics become less effective, phage therapy offers a promising alternative. According to the World Health Organization, global antibiotic resistance rates are estimated to reach 10 million deaths annually by 2050, making the demand for innovative treatments more urgent than ever.

Advancements in Biotechnology and Genomics: Rapid advancements in biotechnology and genomics are significantly boosting the demand for the Phage Therapy market. Techniques like metagenomics are instrumental in discovering new phages from various environments, broadening the range of potential treatments. Innovations in genetic engineering and synthetic biology enable the customization and refinement of phages to achieve greater specificity, stability, and safety.

Regulatory Support and Clinical Trials: Regulatory agencies are moving towards establishing transparent guidelines and pathways for regulatory clearance of phage-based treatments. Pivotal clinical trials play a vital role in providing the necessary evidence to showcase the therapeutic advantages of phage therapy across diverse conditions, from wound infections to respiratory and urinary tract infections. These trials not only offer valuable insights into the safety and efficacy of phage-based treatments but also instill confidence among healthcare providers and patients.

Personalized Medicine: The emphasis on personalized medicine, which tailors treatment to the individual characteristics of each patient and their bacterial infections, is a significant driver. This personalized approach enhances the effectiveness of treatments and reduces the likelihood of adverse reactions, fostering greater patient compliance. Ongoing research into phage selection processes is essential for developing targeted therapies.

3. Limiting Factors of Phage Therapy Market

Alternative Treatments: The presence of alternative treatments for antibiotic-resistant infections may hinder the growth of the Phage Therapy market. Many bacterial infections can still be treated with antibacterial agents and prevented by vaccinations. Additionally, an increasing number of drugs are entering the market for the treatment of antibiotic-resistant infections, providing competition to phage therapy.

Regulatory and Standardization Challenges: The success of phage therapy is highly dependent on the safety of phage preparations, which raises manufacturing and formulation challenges. Regulatory policies and standards for phage therapy are not yet perfect. The production of phages for therapy must comply with strict regulations, but no clear guidelines have been developed specifically for phage manufacturing. The development of phage management standards is also a major problem, and the general procedures and implementation standards of biopharmaceuticals must be followed. However, due to the differences between phages and other biological drugs, there are many difficulties in formulating relevant standards.

Public Awareness and Acceptance: Despite the potential benefits of phage therapy, public awareness and acceptance remain low. This can limit the market’s growth as patients and healthcare providers may be hesitant to adopt new and less familiar treatments. Educational efforts and increased awareness campaigns are needed to overcome this barrier.

In conclusion, the Phage Therapy market is poised for significant growth, driven by the increasing prevalence of antibiotic-resistant infections, advancements in biotechnology, regulatory support, and the potential of personalized medicine. However, the market also faces challenges from alternative treatments, regulatory hurdles, and the need for increased public awareness and acceptance.

4. Analysis of Phage Therapy Market Segment in 2024

Product Types

DsDNA Bacteriophage

DsDNA Bacteriophage is the dominant type in the market, with a significant share of the total revenue. In 2024, it is expected to generate the highest revenue of $182.32 million.

SsDNA Bacteriophage

SsDNA Bacteriophage has a smaller market share but is growing rapidly. In 2024, it is expected to contribute significantly to the market revenue of $15.72 milion.

SsRNA Bacteriophage

SsRNA Bacteriophage has a relatively small market share but is gaining traction. In 2024, it is expected to generate a modest revenue with $3.12 milion.

In 2024, DsDNA Bacteriophage has the largest market share, accounting for over 90% of the total revenue. However, SsRNA Bacteriophage is expected to have the fastest growing rate, driven by its unique applications and potential in treating viral infections. The market for phage therapy is dynamic, with each type contributing to the overall growth and development of the industry.

Different Applications of Phage Therapy Market in 2024

Animal Health

Animal Health is the largest application segment in the Phage Therapy market. In 2024, it is expected to generate the highest revenue of $88.93 million. Animal Health holds the largest share of the market, due to the widespread use of phage therapy in treating bacterial infections in livestock and poultry. The growth rate of Animal Health is steady, driven by the increasing demand for safe and effective treatments in the animal husbandry industry.

Human Health

Human Health is a significant application segment, with a substantial revenue of $53.51 million in 2024. The growth rate of Human Health is expected to be high, driven by the increasing prevalence of antibiotic-resistant infections and the need for alternative treatments.

Agriculture

Agriculture is an emerging application segment, with a growing revenue of $33.73 million in 2024. The growth rate of Agriculture is expected to be high, driven by the increasing demand for sustainable and eco-friendly solutions in crop protection.

Food Industry

The Food Industry is a growing application segment, with a modest revenue of $23.89 million in 2024. The growth rate of the Food Industry is expected to be significant, driven by the increasing demand for food safety and the use of phage therapy in preventing bacterial contamination.

In 2024, Animal Health has the largest market share. However, Human Health is expected to have the fastest growing rate, driven by the increasing prevalence of antibiotic-resistant infections and the need for alternative treatments.

Market Revenue by Segment

5. Regional Phage Therapy Market Size by Major in 2024

North America

North America is a leading region in the Phage Therapy market, with a revenue of $99.71 million in 2024. It is expected to generate a significant portion of the total market revenue. The growth rate in North America is steady, driven by advanced healthcare infrastructure, high awareness of antibiotic resistance, and significant investment in research and development.

The region benefits from a strong regulatory environment that supports the development and approval of new therapies. Additionally, the presence of major biotechnology and pharmaceutical companies in the region drives innovation and market expansion.

Europe

Europe is another significant region in the Phage Therapy market, with a considerable revenue share in 2024. It is expected to contribute a large portion of the total market revenue of $67.45 million in 2024.

Europe has a long history of phage therapy research and a well-established regulatory framework. The region also benefits from a high level of public and private investment in healthcare and biotechnology.

Asia-Pacific

The Asia-Pacific region is emerging as a major player in the Phage Therapy market, with a growing revenue of $30.26 million in 2024. It is expected to show significant growth in the coming years. Asia-Pacific has the fastest-growing rate among all regions, driven by rapid economic development, increasing healthcare spending, and a growing awareness of antibiotic resistance. The region’s large population and growing middle class are driving demand for advanced healthcare solutions. Additionally, the increasing prevalence of antibiotic-resistant infections in the region is creating a strong need for alternative therapies.

South America

South America is a growing region in the Phage Therapy market, with a modest revenue of $7.89 million in 2024. It is expected to contribute a small but growing portion of the total market revenue.The growth rate in South America is significant, driven by improving healthcare infrastructure and increasing investment in biotechnology.The region is focusing on developing its healthcare sector, which is creating opportunities for the adoption of new therapies. Additionally, the presence of major agricultural and livestock industries in the region is driving demand for phage therapy in animal health.

Middle East and Africa

The Middle East and Africa region is a smaller but growing market for Phage Therapy, with a modest revenue of $2.78 million in 2024. It is expected to contribute a small portion of the total market revenue. The growth rate in the Middle East and Africa is moderate, driven by increasing healthcare awareness and investment in the region. The region is focusing on improving healthcare outcomes and reducing the burden of infectious diseases. Additionally, the growing population and increasing economic development are creating opportunities for the adoption of new therapies.

In 2024, North America and Europe are the largest regional markets by size, each contributing significantly to the total market revenue. However, the Asia-Pacific region is the fastest-growing region, driven by rapid economic development, increasing healthcare spending, and a growing awareness of antibiotic resistance. The dynamic nature of the Phage Therapy market across different regions highlights the global potential for this innovative therapy.

Global Phage Therapy Market Size (M USD) by Regions in 2024

6. Top 3 Companies in the Phage Therapy Market

CJ Cheiljedang

CJ Cheiljedang is a South Korean food company based in Seoul, established in 1953. It manufactures food ingredients, ambient, frozen and chilled packaged food products, pharmaceuticals, and biotechnology products. The company has a global sales network and is known for its innovative approach to biotechnology.

CJ Cheiljedang offers a range of phage therapy products, including CJ BIO BIOTECTOR, which is the world’s first bacteriophage cocktail of feed additive. It is used in animal health to prevent and treat bacterial infections in livestock.

NPO Microgen

NPO Microgen is a Russian company established in 2003, with its headquarters in Russia. It is known for developing and producing vaccines, toxoids, blood products, bacteriophages, diagnostic preparations, growth media, and allergens. The company has a strong presence in the European market.

NPO Microgen offers a variety of phage therapy products, including E.coli-Proteus bacteriophage, Streptococcus bacteriophage, and Complex pyobacteriophage. These products are used in human health to treat and prevent various bacterial infections.

Micreos

Micreos is a Dutch company established in 2005, with its headquarters in the Netherlands. It is a leading developer of phage technology for targeted control of bacteria, focusing on the food industry and human health.

Micreos offers products such as PhageGuard, which is used in the food industry to prevent bacterial contamination, and Gladskin, which is used in human health to treat inflammatory skin conditions. The company’s products are known for their natural and organic approach to food safety and health.

Major Players